Related Experiment Video

Updated: May 25, 2025

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

111.3K

Antitumor Activity of USP7 Inhibitor GNE-6776 in Non-Small Cell Lung Cancer Involves Regulation of

Lipeng Wu1, Long Lin2, Meng Yu1

  • 1Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Pharmaceuticals (Basel, Switzerland)
|February 26, 2025
PubMed

Insights

The USP7 inhibitor GNE-6776 shows significant anti-tumor effects against non-small cell lung cancer (NSCLC) by inhibiting cell growth and promoting apoptosis. This drug holds promise for developing new NSCLC therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
  • Targeting specific molecular pathways is crucial for developing effective NSCLC therapies.

Purpose of the Study:

  • To investigate the anti-cancer effects and underlying mechanisms of the USP7 inhibitor GNE-6776 in human NSCLC cells.
  • To evaluate the therapeutic potential of GNE-6776 for NSCLC treatment.

Main Methods:

  • Analysis of USP7 expression in lung cancer tissues.
  • In vitro studies using A549 and H1299 NSCLC cell lines treated with GNE-6776.
  • Assessment of cell proliferation, migration, invasion, apoptosis, mitochondrial membrane potential, and cell cycle.
  • Western blot analysis for protein expression and signaling pathway modulation (PI3K/AKT/mTOR, Wnt/β-catenin).
  • In vivo evaluation using a xenograft tumor model in nude mice.

Main Results:

  • GNE-6776 inhibited NSCLC cell proliferation, migration, and invasion in a dose-dependent manner.
  • The compound induced apoptosis and G1 cell cycle arrest, decreased mitochondrial membrane potential, and suppressed epithelial-mesenchymal transition (EMT) markers.
  • GNE-6776 downregulated the PI3K/AKT/mTOR and Wnt/β-catenin pathways and significantly inhibited tumor growth in vivo.
  • Reduced expression of CDK6, C-myc, and N-cadherin, with increased GSK3β expression observed in tumor tissues.

Conclusions:

  • GNE-6776 exhibits potent in vitro and in vivo anti-tumor activity against NSCLC.
  • The drug functions by inhibiting EMT and modulating key signaling pathways, making it a potential therapeutic candidate for NSCLC.
Keywords:
EMTGNE-6776USP7 inhibitorcell cyclenon-small cell lung cancer (NSCLC)

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K